Why the study?
Does pharmacological treatment improve outcomes in elderly patients with isolated systolic hypertension?
Does pharmacological treatment improve outcomes in elderly patients with isolated systolic hypertension?
This review highlights that while pharmacological treatment of isolated systolic hypertension in the elderly improves cardiovascular outcomes, it remains largely untreated and uncontrolled.
Supports prioritizing isolated systolic hypertension treatment in the elderly; leaves open optimal control strategies and implementation.
Isolated systolic hypertension is the predominant type of hypertension in the elderly and is associated with cardiovascular complications such as stroke, coronary heart disease and heart failure. In this review, the role of arterial stiffness, endothelial function, atherosclerosis and oxidative stress in the pathogenesis of isolated systolic hypertension is extensively discussed. Placebo-controlled intervention trials such as the Systolic Hypertension in Europe Trial and the Systolic Hypertension in the Elderly Program have clearly shown that pharmacological treatment of isolated systolic hypertension improves outcome in the elderly. Nevertheless, isolated systolic hypertension remains the major subtype of untreated and uncontrolled hypertension.
No takes yet. Share an insight, caveat, or question.
Thijs et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: